Trial Profile
Open-label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Single or Multiple Applications of StrataGraft Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Human skin replacement (Primary)
- Indications Burns; Wounds
- Focus Therapeutic Use
- Sponsors Stratatech
- 03 Jan 2020 Status changed from active, no longer recruiting to discontinued.
- 16 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2018 Planned End Date changed from 1 Oct 2018 to 1 Feb 2020.